Patients with epithelioid MPM (n¼305) were categorized using modified pleural Response Evaluation Criteria in Solid Tumors by whether they responded to treatment. Median progression-free survival (PFS) and overall survival (OS) were estimated and hazard ratios for responders and nonresponders were estimated and compared using the log-rank test. Multivariable Cox proportional hazards models were used to adjust for baseline prognostic factors. Results: Patients who responded to frontline therapy had a significantly longer OS (hazard ratio, 0.34; 95% CI, 0.24-0.49; median, 20.6 months; 95% CI, 15.3 months to not reached) than did those who did not respond (median, 9.4 months; 95% CI, 8.1-11.0 months) (P<.001). Similarly, responders had a significantly longer PFS (hazard ratio, 0.50; 95% CI, 0.39-0.64; median, 7.8 months; 95% CI, 6.5-8.5 months) than did nonresponders (median, 3.7 months; 95% CI, 2.9-4.3 months) (P<.001). These results were confirmed when adjusting for baseline prognostic factors. We also observed a survival benefit associated with disease stabilization in MPM. Conclusion: Our findings indicate that reduction in tumor burden or disease stabilization determined using modified pleural Response Evaluation Criteria in Solid Tumors is strongly associated with OS and PFS in epithelioid MPM. A lthough commonly used, surrogate end points remain controversial in anticancer drug approvals despite their acceptance by regulatory agencies.
A lthough commonly used, surrogate end points remain controversial in anticancer drug approvals despite their acceptance by regulatory agencies. 1 In fact, one review of oncology drug approvals from 1990 through 2002 found that 68% of approvals were based on end points other than survival. 2 Pharmaceutical industry support of and growing public demand for accelerated access to novel therapies further encourage the use of surrogate end points 3 ; however, these end points must provide reliable and robust surrogates for patient outcomes. Objective response rate (ORR) is commonly used as an end point in early phase clinical trials and is increasingly incorporated in phase 3 clinical trials, but because of the limited duration of response, drug toxicity, or other factors, a response to treatment may not necessarily translate into improved survival.
Despite the dismal prognosis of malignant pleural mesothelioma (MPM), targeted therapies, 4 auxotrophic strategies, 5 and immunotherapy 6, 7 exhibit emerging signals of improved patient outcomes. These pharmaceutical developments have led to a proliferation of clinical trial opportunities for patients with MPM, many of which incorporate ORR into their trial design. To date, as the effect of reduction in tumor burden on survival in MPM remains indeterminate, the widespread use of ORR as a study outcome mandates clinical validation.
Assessment of disease progression remains challenging in MPM, and standard Response Evaluation Criteria in Solid Tumors 8 were not designed to measure pleural disease. Modified pleural Response Evaluation Criteria in Solid Tumors (mRECIST) 9 have been adopted by mesothelioma experts for measuring disease response in clinical practice and in clinical trials for MPM. Combination therapy with cisplatin and pemetrexed represents the only US Food and Drug Administration (FDA)eapproved regimen for MPM. In the clinical trial that led to the approval of this regimen, patients were randomized to receive either cisplatin alone or cisplatin and pemetrexed. The median survival for patients who received the combination was 12.1 months compared with 9.3 months for those who received cisplatin alone. 10 The effects of treatment response on survival have not been reported for this clinical trial. Herein, we report the relationship of treatment response based on mRECIST to progression-free survival (PFS) and overall survival (OS) in patients with epithelioid MPM treated with the only FDA-approved regimen for this disease.
PATIENTS AND METHODS
We requested and received approval from the sponsor (Eli Lilly and Company) to use the data collected from the clinical trial that led to the approval of cisplatin and pemetrexed by the FDA for MPM 10 through ClinicalStudyDataRequest.com. The original clinical trial was conducted from April 1999 through March 2001. Because most patients had epithelioid MPM and disease responses were rare in patients with sarcomatoid MPM, we limited our analysis to the subset of patients with epithelioid mesothelioma. In addition, patients were administered folic acid and vitamin B 12 to reduce the toxicity of pemetrexed part way through this clinical trial. Accordingly, we assessed outcomes in all cases of epithelioid MPM and in those who received supplementation. Responses were categorized using mRECIST 9 as determined by the treating investigators. Response assessment was performed per protocol, which was at least once just before every other treatment while a patient was receiving study therapy and approximately every 6 weeks after the completion of study therapy. Treatments were scheduled every 21 days. Progression-free survival and OS were analyzed to assess differences between responders and nonresponders. Kaplan-Meier methods were used to estimate survival rates.
Cox proportional hazards models were used to estimate the magnitude of risk of death/progression of responders compared with nonresponders or of responders and those with stable disease (SD) compared with those with progression of disease (PD). To assess the robustness of these results, multivariable Cox proportional hazards models including previously reported baseline prognostic factors (performance status, stage, age, white blood cell count, hemoglobin concentration, platelet count, and patient-reported pain) were used. 11, 12 The Mayo Clinic Institutional Review Board approved this study.
RESULTS
We analyzed 305 patients with epithelioid MPM. There were 98 patients with a complete response (CR) or partial response (PR) (32%), 126 patients with SD as their best response (41%), and 81 patients with PD (27%). We identified that patients who responded (CR and PR) to frontline therapy with cisplatin or cisplatin and pemetrexed had a significantly longer OS (hazard ratio [HR], 0.34; 95% CI, 0.24-0.49; median 20.6 months; 95% CI, 15.3 months to not reached) than did those who did not respond (SD or PD) to treatment (median, 9.4 months; 95% CI, 8.1-11.0 months) (P<.001) (Figure 1, A) . Similarly, patients who responded to frontline therapy had a significantly longer PFS (HR, 0.50; 95% CI, 0.39-0.64; median, 7.8 months; 95% CI, 6.5-8.5 months) than did those who did not respond (median, 3.7 months; 95% CI, 2.9-4.3 months) (P<.001) (Figure 1, B) . These results were confirmed using the multivariable Cox proportional hazards model. The adjusted HR for the OS response group was 0.29 (95% CI, 0.20-0.41). Similarly, results for PFS were confirmed as the adjusted HR for the PFS response group was 0.45 (95% CI, 0.35-0.59).
Our analysis of the effects of treatment response on survival restricted to patients who received supplementation with folic acid and vitamin B 12 (n¼229) included 80 patients with CR or PR (35%), 93 patients with SD as their best response (41%), and 56 patients with PD (24%). We observed that patients with epithelioid MPM who received supplementation and who responded to frontline therapy had a significantly longer OS (HR, 0.36; 95% CI, 0.23-0.55; median, 18.4 months; 95% CI, 14.9 months to not reached) than did those who did not respond to treatment (median, 10.8 months; 95% CI, 8.3-12.7 months) (P<.001) (Figure 1, C) . Similarly, patients who received supplementation and who responded to frontline therapy had a significantly longer PFS (HR, 0.57; 95% CI, 0.42-0.75; median, 7.8 months; 95% CI, 6.1-8.5 months) than did those who did not respond to treatment (median, 3.9 months; 95% CI, 2.9-4.4 months) (P<.001) (Figure 1,  D) . Again, these results were confirmed with multivariable modeling including baseline prognostic factors. The adjusted HR for the OS response group was 0.29 (95% CI, 0.19-0.45). Similarly, results for PFS were confirmed as the adjusted HR for the PFS response group was 0.50 (95% CI, 0.37-0.67).
To determine the effects of response to treatment or disease stabilization on survival, we then grouped patients with CR, PR, and SD as their best response (n¼224) and compared them with patients with PD (n¼81). We first analyzed all patients with epithelioid MPM. We observed that patients with response to treatment or disease stabilization had a significantly longer OS (HR, 0.24; 95% CI, 0.17-0.33; median, 14.9 months; 95% CI, 12.8-17.2 months) than did those with PD (median, 5.7 months; 95% CI, 4.0-6.5 months) (P<.001) (Figure 2, A) . Similarly, patients with response to treatment or disease stabilization had a significantly longer PFS (HR, 0.18; 95% CI, 0.14-0.24; median, 6.3 months; 95% CI, 5.8-7.0 months) than did those with PD (median, 1.4 months; 95% CI, not determined) (P<.001) (Figure 2, B) . These results were confirmed with multivariable modeling including baseline prognostic factors. The adjusted HR for OS was 0.22 (95% CI, 0.16-0.31), and for PFS it was 0.19 (95% CI, 0.14-0.25).
We then restricted our analysis to patients who received supplementation with folic acid and vitamin B 12 . We observed that patients with response to treatment or disease stabilization who received supplementation had a significantly longer OS (HR, 0.25; 95% CI, 0.18-0.37; median, 15.4 months; 95% CI, 13.3-17.6 months) than did those with PD (median, 5.9 months; 95% CI, 4.4-6.7 months) (P<.001) (Figure 2, C) . Similarly, patients with response to treatment or disease stabilization had a significantly longer PFS (HR, 0.22; 95% CI, 0.16-0.31; median, 6.3 months; 95% CI, 5.8-7.3 months) than did those with PD (median, 1.4 months; 95% CI, 1.4-1.5 months) (P<.001) (Figure 2, D) . These results were confirmed with multivariable modeling including baseline prognostic factors. The adjusted HR for OS was 0.23 (95% CI, 0.15-0.34), and for PFS it was 0.20 (95% CI, 0.14-0.29).
Finally, we separately assessed the survival of patients with CR/PR, SD, and PD. Among all patients and patients who received supplementation, patients with CR/PR were found to have best OS and PFS. For patients with SD as their best response to treatment, the OS and PFS outcomes were between those of responders and those with PD ( Figure 3 and Table) .
DISCUSSION
We observed that treatment response to singleagent cisplatin or the combination cisplatin and pemetrexed in patients with epithelioid MPM as defined by mRECIST is strongly associated with OS and PFS. These findings are supportive of the use of ORR as an end point in clinical trials for MPM, but there are caveats to the indiscriminate acceptance of such use. Progression-free survival probability Novel therapeutic approaches, especially immunotherapies, challenge our traditional response assessments, and a radiographic increase in the size of a lesion may actually represent infiltration of tumor by lymphocytes rather than disease progression. 13 In the clinic, it can be challenging to distinguish cases of disease progression from pseudoprogression with immunotherapy. In addition, targeted therapies may result in dramatic reductions in tumor burden, but these responses may be short-lived and may not always correlate with survival benefits. We also observed that disease stabilization was associated with a survival benefit. Along these lines, end points such as PFS may be more appropriate than response rates for investigational or therapeutic agents that stabilize tumors rather than shrink them.
The original proposal for mRECIST evaluated how response to cisplatin and gemcitabine affected survival in 73 patients with MPM and identified a significant correlation between treatment responses and improved OS (P¼.03). 9 Because the FDA approved the frontline regimen of cisplatin and pemetrexed for MPM, the cisplatin and gemcitabine regimen is less commonly used. Regardless, our results support this observation. It is important to note that we used the mRECIST-based responses as determined by the treating investigators. Secondary review of the data by the FDA did not confirm all these responses 14 ; however, it remains unclear whether the FDA used mRECIST or RECIST in their assessment of treatment responses, which may explain this discrepancy. Others have studied Progression-free survival probability surrogate end points in mesothelioma. A recent retrospective review of patient outcomes from 17 phase 2 clinical trials conducted by Cancer and Leukemia Group B or North Central Cancer Treatment Group (now the Alliance) did not identify a strong association between PFS and OS. 15 There were few responses in the clinical trials in this analysis, and the association between treatment response and survival was not addressed, which limits comparison with our study. In the study most similar to ours, patients who were treated in phase 2 clinical trials conducted by the European Organisation for Research and Treatment of Cancer were assessed for response at a 42-day landmark. Overall survival was significantly different among those with PR (12.8 months), SD (9.4 months), or PD (3.4 months) (P<.0001). 16 A separate study based on many of the same patients assessed PFS rates at 9 and 18 weeks and found that both were predictive of OS. 17 To limit selection bias, landmark analysis, removing patients who died or were censored before the landmark, was performed in these studies. Consequently, control arms are less penalized for early deaths; however, a significant proportion of patients (16.8% and 27.9%, respectively) were removed for the PFS rate analysis at 9 and 18 weeks. 17 We argue that although a landmark analysis with a more distant time point would assess the effect of the durability of response on survival, too distant of an end point may not provide a meaningful comparison. To minimize such bias in our study, we used multivariable Cox proportional hazards models to adjust for known prognostic factors in mesothelioma. Regardless of these differences in approaches, similar conclusions can be made for our studies: that responses to treatment are associated with an OS benefit in MPM. Despite our observations, we acknowledge that mRECIST remain suboptimal for a spatially complex disease such as MPM. More comprehensive linear measurements and possibly serial volumetric assessments of tumor size using computed tomography, magnetic resonance imaging, or positron emission tomography/computed tomography represent future opportunities for improvement. [18] [19] [20] [21] More recently, the addition of bevacizumab to cisplatin and pemetrexed improved OS and PFS compared to cisplatin and pemetrexed alone. 22 It is not certain whether the addition of an antievascular endothelial growth factor agent affects the association of response and survival, as it was not reported in this study. 22 Even though the addition of bevacizumab to cisplatin and gemcitabine did not improve PFS or OS in patients with MPM, 23 its inclusion with cisplatin and pemetrexed is associated with a strong incremental benefit in patient survival.
The critical standard outcomes for oncology clinical trials are OS and quality of life, but crossover to subsequent therapies and competing risks influence the measurement of survival. Our results are confounded by second-line therapies that were administered to 42% of the patients (189 of 448) who participated in the frontline clinical trial. 24 Those who received second-line therapy had significantly improved survival compared with those who did not. Because of the limited numbers and low treatment response rates, we excluded patients with sarcomatoid MPM from our analysis; however, we have published the response rates of these patients previously. 25 Consequently, our present findings should not be extended to other subtypes of MPM. In addition, we are uncertain how our findings apply to subsequent lines of therapy, other chemotherapeutic regimens, targeted agents, or immunotherapy. Some investigators argue that there is no standard of care second-line therapy for MPM and that clinical trial participation, in clinical trials that stratify based on prognostic scores, is desirable. 26 We share that opinion. Regardless, the strong association we observed of ORR with survival supports the inclusion of ORR in early phase clinical trials or as secondary end points in phase 3 trials. The decision to include ORR as an end point should be based on the nature of the therapeutic agent being studied, guidance from the FDA or other relevant regulatory agencies, and methods and frequency of response assessment.
CONCLUSION
Our findings indicate that reduction in tumor burden or disease stabilization determined using mRECIST is strongly associated with OS and PFS in epithelioid MPM.
